Biocytogen Pharmaceuticals (Beijing) Co., Ltd. announced the launch of a new sub-brand, RenBiologics?, to represent the company?s antibody discovery business division. RenBiologics business will cover out-licensing/co-development of the company?s extensive library of fully human antibodies, as well as licensing of RenMice®, the company?s fully human antibody/TCR discovery platforms. The RenBiologics logo features an antibody with human-centric design elements, highlighting Biocytogen's expertise in discovering fully human antibodies; the encircled design underscores the company?s dedication to becoming a global resource of fully human antibodies to expedite the development of novel antibody-based therapeutics.
Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
Equities
2315
CNE100005D27
Biotechnology & Medical Research
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
9.59 CNY | +0.31% | -0.10% | -19.95% |
May. 06 | Biocytogen Enters into Evaluation and Potential Licensing Agreement with Biocopy for TCR-mimic Antibodies | CI |
Apr. 26 | Biocytogen Pharmaceuticals' Loss Narrows in 2023 | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-19.95% | 491M | |
+53.28% | 63.85B | |
-1.69% | 41.83B | |
+40.26% | 40.47B | |
-10.02% | 27.17B | |
+14.68% | 26.52B | |
-20.67% | 18.69B | |
+3.34% | 12.73B | |
+22.17% | 12.11B | |
+28.99% | 12.07B |
- Stock Market
- Equities
- 2315 Stock
- News Biocytogen Pharmaceuticals (Beijing) Co., Ltd.
- Biocytogen Pharmaceuticals Co., Ltd. Announces Launch of New Sub-Brand, RenBiologics